BIM 23268

Drug Profile

BIM 23268

Alternative Names: BIM 23268D

Latest Information Update: 04 May 2007

Price : $50

At a glance

  • Originator Biomeasure Inc
  • Class
  • Mechanism of Action Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 25 Aug 2003 No development reported - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
  • 03 Jun 2003 Beaufour-Ipsen is now called Ipsen
  • 12 Dec 2001 Preclinical development for Type-2 diabetes mellitus in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top